Reuters logo
BRIEF-Kura Oncology reports updated clinical activity data in ongoing phase 2 trial for tipifarnib
March 6, 2017 / 12:43 PM / 9 months ago

BRIEF-Kura Oncology reports updated clinical activity data in ongoing phase 2 trial for tipifarnib

March 6 (Reuters) - Kura Oncology Inc

* Kura Oncology reports updated clinical activity data in ongoing phase 2 trial for tipifarnib

* Kura Oncology - tipifarnib was generally well tolerated with adverse events consistent with its known safety profile

* Kura Oncology - anticipate additional results from ongoing phase 2 trial of tipifarnib in hras mutant scchn will be available during second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below